Citius Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $23,531,894.
Profit Margin
| 2012 | 0 | -22.00K | |
|---|---|---|---|
| 2013 | 0 | -31.36K | |
| 2014 | 0 | 0 | |
| 2015 | 3.06K | -2.90M | -94659.75% |
| 2016 | 806 | -8.29M | -1029242.93% |
| 2017 | 0 | -8.29M | |
| 2018 | 75K | -12.53M | -16715.52% |
| 2019 | 90K | -15.56M | -17291.27% |
| 2020 | 0 | -17.54M | |
| 2021 | 0 | -23.05M |
CTXRW Income Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 90K | 75K | 0 | 806 | 3.06K | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 75K | 0 | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 90K | 0 | 0 | 806 | 3.06K | 0 | 0 | 0 |
Operating exp. | ||||||||||
Research and development | 12.24M | 8.81M | 8.59M | 6.56M | 2.93M | 2.93M | 1.79M | 0 | 0 | 0 |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 23.53M | 17.71M | 15.59M | 13.78M | 7.44M | 7.44M | 3.22M | 0 | 28.11K | 19.61K |
Operating income | -23.53M | -17.71M | -15.59M | -13.78M | -9.98M | -7.44M | -3.22M | 0 | -28.11K | -19.61K |
Other income (expenses), net | 477.46K | 162.6K | 31.16M | 1.25M | 1.69M | -846.40K | 327.66K | 0 | -3.25K | -2.38K |
Income before tax | -23.05M | -17.54M | 15.56M | -12.53M | -8.29M | -8.29M | -2.90M | 0 | -31.36K | -22.00K |
Income tax expense | 488.29K | 178.27K | 31.17M | 1.26M | 1.69M | -837.41K | 0 | 0 | 0 | 0 |
Net income | -23.05M | -17.54M | -15.56M | -12.53M | -8.29M | -8.29M | -2.90M | 0 | -31.36K | -22.00K |
Earnings per share | ||||||||||
Basic EPS | -0.66 | -0.5 | -0.77 | -1.17 | -2.29 | -0.15 | -0.09 | 0 | -0.00 | -0.00 |
Diluted EPS | -0.66 | -0.5 | -0.77 | -1.17 | -2.29 | -0.15 | -0.09 | 0 | -0.00 | -0.00 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |